The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...

Hundreds of children with a rare and severe form of epilepsy are hoping a new drug being rolled out on the NHS may provide a better quality of life. Fenfluramine has been recommended by the ...

Hundreds of children in England with a rare and severe form of epilepsy are set to benefit from a new drug being rolled out on the NHS. Fenfluramine has been recommended by the National Institute for ...

The study applied iDOMO to triple-negative breast cancer, a particularly aggressive and difficult-to-treat form ... drug ...

Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection. In a regulatory filing made after market hours ...

PTC Therapeutics has announced that the FDA has accepted its new drug application (NDA) for vatiquinone to treat Friedreich's ataxia (FA). The application has been granted priority review, with a ...

TUESDAY, Feb. 18, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular ...

NEW YORK – Boehringer Ingelheim on Wednesday said the US Food and Drug Administration accepted its new drug application for the irreversible tyrosine kinase inhibitor zongertinib as a treatment for ...

The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA). The new tablet is ...